Nuveen’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-845,023
| Closed | -$43.7M | – | 3308 |
|
|
2022
Q3 | $43.7M | Sell |
845,023
-46,655
| -5% | -$1.93M | 0.02% | 571 |
|
|
2022
Q2 | $22.1M | Buy |
891,678
+332,802
| +60% | +$7.34M | 0.01% | 987 |
|
|
2022
Q1 | $13.6M | Buy |
558,876
+173,453
| +45% | +$4.87M | ﹤0.01% | 1448 |
|
|
2021
Q4 | $14M | Buy |
385,423
+178,325
| +86% | +$6.26M | ﹤0.01% | 1469 |
|
|
2021
Q3 | $3.54M | Sell |
207,098
-12,129
| -6% | -$189K | ﹤0.01% | 2398 |
|
|
2021
Q2 | $2.94M | Sell |
219,227
-253,488
| -54% | -$6.24M | ﹤0.01% | 2529 |
|
|
2021
Q1 | $24.2M | Buy |
472,715
+254,402
| +117% | +$15.3M | 0.01% | 1179 |
|
|
2020
Q4 | $1.76M | Sell |
218,313
-279,496
| -56% | -$16M | ﹤0.01% | 2572 |
|
|
2020
Q3 | $4.01M | Buy |
497,809
+63,428
| +15% | +$3.41M | ﹤0.01% | 2038 |
|
|
2020
Q2 | $3.5M | Sell |
434,381
-15,006
| -3% | -$817K | ﹤0.01% | 2083 |
|
|
2020
Q1 | $18.1M | Buy |
449,387
+58,534
| +15% | +$2.49M | 0.01% | 958 |
|
|
2019
Q4 | $15.5M | Buy |
390,853
+139,893
| +56% | +$2.46M | 0.01% | 1323 |
|
|
2019
Q3 | $1.7M | Sell |
250,960
-152,319
| -38% | -$1.14M | ﹤0.01% | 2478 |
|
|
2019
Q2 | $3.75M | Buy |
+403,279
| New | +$4.67M | ﹤0.01% | 2145 |
|
Other funds holding CCXI
Nuveen's CCXI Position: Q4 2022 in Review
Nuveen sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 845,023 shares — an estimated $43.7M sold.
Nuveen first reported a position in CCXI in Q2 2019 and held it in 14 quarters. The position peaked at $43.7M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Nuveen reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Nuveen sold 845,023 ChemoCentryx, Inc. shares in Q4 2022, an estimated $43.7M.
- Nuveen first reported a position in ChemoCentryx, Inc. in Q2 2019 and held it in 14 quarters.
- Nuveen's ChemoCentryx, Inc. position peaked at $43.7M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Nuveen's 13F filing for Q4 2022, filed 14 Feb 2023.